Do we need a different strategy for HPV screening and vaccination in East Asia? [3]

International Journal of Cancer

Volumn 119, Issue 11, 2006, Pages 2713-2715

  Miura, Shiho ^a   Matsumoto, Koji ^b   Oki, Akinori ^b   Satoh, Toyomi ^b   Tsunoda, Hajime ^b   Yasugi, Toshiharu ^a   Taketani, Yuji ^a   Yoshikawa, Hiroyuki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ADENOSQUAMOUS CARCINOMA; ASIA; CANCER GRADING; CANCER GROWTH; CANCER RISK; CHINA; DNA DETERMINATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; JAPAN; KOREA; LETTER; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

FAR EAST; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SPECIES SPECIFICITY;

EID: 33750619919     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22195     Document Type: Letter

References (27)

1. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
2. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ;International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A metaanalysis. Br J Cancer 2003;88:63-73.
4. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
5. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
6. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
7. Nakagawa S, Yoshikawa H, Onda T, Kawana T, Iwamoto A, Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 1996;78:1935-41.
8. Nakagawa S, Yoshikawa H, Kimura M, Kawana K, Matsumoto K, Onda T, Kino N, Yamada M, Yasugi T, Taketani Y. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer 1999;79:589-94.
9. Yoshikawa H, Nagata C, Noda K, Nozawa S, Yajima A, Sekiya S, Sugimori H, Hirai Y, Kanazawa K, Sugase M, Shimizu H, Kawana T. Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer 1999;80:621-4.
10. Minaguchi T, Yoshikawa H, Nakagawa S, Yasugi T, Yano T, Iwase H, Mizutani K, Shiromizu K, Ohmi K, Watanabe Y, Noda K, Nishiu M et al. Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix. Cancer Lett 2004;210:57-62.
11. Nakagawa H, Sugano K, Fujii T, Kubushiro K, Tsukazaki K, Nozawa S. Frequent detection of human papilloma viruses in cervical dysplasia by PCR single-strand DNA-conformational polymorphism analysis. Anticancer Res 2002;22:1655-60.
12. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003;88:1883-8.
13. Matsukura T, Sugase M. Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. Virology 2004;324:439-49.
14. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001;10:45-52.
15. Yoshino K, Enomoto T, Nakamura T, Sun H, Ozaki K, Nakashima R, Wada H, Saitoh J, Watanabe Y, Noda K, Murata Y. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer 2000;85:6-13.
16. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003;91:476-85.
17. Miwa K, Miyamoto S, Kato H, Imamura T, Nishida M, Yoshikawa Y, Nagata Y, Wake N. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 1995;71:219-26.
18. Iwasaka T, Matsuo N, Yokoyama M, Uchiyama K, Fukuda H, Sugimori H. Prospective follow-up of Japanese women with cervical intraepithelial neoplasia and various human papillomavirus types. Int J Gynecol Obstet 1998;62:269-77.
19. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004;189:1829-32.
20. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000;79:294-9.
21. Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, Li GD, Tam JS et al. Prevalence of human papillomavirus in cervical cancer, a multicenter study in China. Int J Cancer 2002;100:327-31.
22. Lai HC, Sun CA, Yu MH, Chen HJ, Liu HS, Chu TY. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. Int J Cancer 1999;84:553-7.
23. Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997;70:408-11.
24. Lin QQ, Yu SZ, Qu W, Cruz Y, Burk RD. Human papillomavirus types 52 and 58. Int J Cancer 1998;75:484,485.
25. Stephen AL, Thompson CH, Tattersall MH, Cossart YE, Rose BR. Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China. Int J Cancer 2000;86:695-701.
26. Hwang TS, Jeong JK, Park M, Han HS, Choi HK, Park TS. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. Gynecol Oncol 2003;90:51-6.
27. Bulkmans NW, Bleeker MC, Berkhof J, Voornorst FJ, Snijders PJ, Meijer CJ. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005;117:177-81.